`SALES AT EX-MANUFACTURER PRICE
`U.S. DOLLARS BY PRODUCT
`Q4 2012 – Q3 2014
`
`2012
`
`Q4
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`$481,929,627
`
`$34,208,377
`
`$486,715,580
`$14,328,948
`$43,543,924
`
`$483,299,055
`$63,999,957
`$49,544,835
`
`$486,184,532
`$78,256,141
`$52,681,394
`
`$494,688,423
`$82,852,340
`$88,655,837
`
`$513,154,068
`$84,350,865
`$125,234,464
`
`$536,125,168
`$78,062,725
`$142,152,239
`
`$570,743,034
`$77,866,869
`$157,678,111
`
`$4,052,839,487
`$479,717,845
`$693,699,181
`
`$31,138,049
`
`$29,985,339
`
`$26,126,981
`
`$24,222,882
`
`$22,848,420
`
`$22,965,409
`
`$22,052,298
`
`$22,614,230
`
`$201,953,608
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`$547,276,053
`
`$574,573,791
`
`$622,970,828
`
`$641,344,949
`
`$689,045,020
`
`$745,704,806
`
`$778,392,430
`
`$828,902,244
`
`$5,428,210,121
`
`88.1%
`
`6.3%
`
`84.7%
`2.5%
`7.6%
`
`77.6%
`10.3%
`8.0%
`
`75.8%
`12.2%
`8.2%
`
`71.8%
`12.0%
`12.9%
`
`68.8%
`11.3%
`16.8%
`
`68.9%
`10.0%
`18.3%
`
`68.9%
`9.4%
`19.0%
`
`74.7%
`8.8%
`12.8%
`
`5.7%
`
`5.2%
`
`4.2%
`
`3.8%
`
`3.3%
`
`3.1%
`
`2.8%
`
`2.7%
`
`3.7%
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`IV
`Herceptin®
`Kadcyla®
`Perjeta®
`
`Non-IV
`Tykerb®
`
`
`
`Total
`
`IV
`Herceptin®
`Kadcyla®
`Perjeta®
`
`Non-IV
`Tykerb®
`
`
`
`Total
`
`
`
`
`
`Notes & Sources:
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand values.
`Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'
`Values reflect field 'Sales $'.
`Percentage calculated as percent of quarterly total.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2242, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
